Rybrevant 350 mg/7 mL (50 mg/mL) injection Images
Generic Name: amivantamab
This medication has been identified as Rybrevant 350 mg/7 mL (50 mg/mL) injection. It is supplied by Janssen Biotech, Inc.
Rybrevant is used in the treatment of Non-Small Cell Lung Cancer and belongs to the drug class miscellaneous antineoplastics. Rybrevant 350 mg/7 mL (50 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Rybrevant
- Generic Name
- amivantamab
- Strength
- 350 mg/7 mL (50 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Janssen Biotech, Inc.
- National Drug Code (NDC)
- 57894-0501
More about Rybrevant (amivantamab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.